WO2026018152 - PERSONALIZED APPROACHES FOR GENE THERAPY
National phase entry is expected:
Publication Number
WO/2026/018152
Publication Date
22.01.2026
International Application No.
PCT/IB2025/057152
International Filing Date
15.07.2025
Title **
[English]
PERSONALIZED APPROACHES FOR GENE THERAPY
[French]
APPROCHES PERSONNALISÉES POUR LA THÉRAPIE GÉNIQUE
Applicants **
REFLECTION BIOTECHNOLOGIES LIMITED
Inventors
YANG, Richard R.
TSANG, Stephen H.
Priority Data
63/671,689
15.07.2024
US
63/676,023
26.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2599 | |
| EPO | Filing, Examination, Granting | 18772 | |
| Japan | Filing, Examination, Granting | 2462 | |
| South Korea | Filing, Examination, Granting | 2828 | |
| USA | Filing, Examination, Granting | 6790 |
Total:
33,451
Contact Us
Abstract[English]
Compositions and methods of treating, arresting, rescuing, ameliorating, preventing or slowing progression of a disease associated with oxidative stress, lipid peroxidation and/or abnormally high level of (i) reactive oxygen species (ROS) and/or (ii) an aldehyde are described.[French]
L'invention concerne des compositions et des méthodes de traitement, d'arrêt, d'inversion, d'atténuation, de prévention ou de ralentissement de la progression d'une maladie associée à un stress oxydatif, à une peroxydation lipidique et/ou à un niveau anormalement élevé (i) d'espèces réactives de l'oxygène (ERO) et/ou (ii) d'un aldéhyde.